Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline.

Näslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD.

JAMA. 2000 Mar 22-29;283(12):1571-7.

PMID:
10735393
2.

Correlation between Abetax-40-, Abetax-42-, and Abetax-43-containing amyloid plaques and cognitive decline.

Parvathy S, Davies P, Haroutunian V, Purohit DP, Davis KL, Mohs RC, Park H, Moran TM, Chan JY, Buxbaum JD.

Arch Neurol. 2001 Dec;58(12):2025-32. Erratum in: Arch Neurol 2002 Feb;59(2):202.

PMID:
11735776
3.

Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type.

Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, Xiong C, Morris JC, Holtzman DM.

Arch Neurol. 2009 May;66(5):638-45. doi: 10.1001/archneurol.2009.55.

4.

Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM.

Arch Neurol. 2007 Mar;64(3):343-9. Epub 2007 Jan 8.

PMID:
17210801
5.

Cholinergic markers in elderly patients with early signs of Alzheimer disease.

Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, Austin G, Haroutunian V.

JAMA. 1999 Apr 21;281(15):1401-6.

PMID:
10217056
6.

Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease.

Haroutunian V, Purohit DP, Perl DP, Marin D, Khan K, Lantz M, Davis KL, Mohs RC.

Arch Neurol. 1999 Jun;56(6):713-8.

PMID:
10369312
7.

Alzheimer's disease.

De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV.

Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Review.

PMID:
23225010
9.

Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease.

Haroutunian V, Perl DP, Purohit DP, Marin D, Khan K, Lantz M, Davis KL, Mohs RC.

Arch Neurol. 1998 Sep;55(9):1185-91.

PMID:
9740112
10.

Olfactory tau pathology in Alzheimer disease and mild cognitive impairment.

Attems J, Jellinger KA.

Clin Neuropathol. 2006 Nov-Dec;25(6):265-71.

PMID:
17140156
11.

Pyroglutamylated amyloid-β is associated with hyperphosphorylated tau and severity of Alzheimer's disease.

Mandler M, Walker L, Santic R, Hanson P, Upadhaya AR, Colloby SJ, Morris CM, Thal DR, Thomas AJ, Schneeberger A, Attems J.

Acta Neuropathol. 2014 Jul;128(1):67-79. doi: 10.1007/s00401-014-1296-9. Epub 2014 May 27.

PMID:
24861310
12.

Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.

Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T.

Arch Neurol. 2009 Mar;66(3):382-9. doi: 10.1001/archneurol.2008.596.

PMID:
19273758
13.

Synaptic Amyloid-β Oligomers Precede p-Tau and Differentiate High Pathology Control Cases.

Bilousova T, Miller CA, Poon WW, Vinters HV, Corrada M, Kawas C, Hayden EY, Teplow DB, Glabe C, Albay R 3rd, Cole GM, Teng E, Gylys KH.

Am J Pathol. 2016 Jan;186(1):185-98. doi: 10.1016/j.ajpath.2015.09.018.

14.

Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain.

Ingelsson M, Fukumoto H, Newell KL, Growdon JH, Hedley-Whyte ET, Frosch MP, Albert MS, Hyman BT, Irizarry MC.

Neurology. 2004 Mar 23;62(6):925-31.

PMID:
15037694
15.

Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging.

Wang DS, Lipton RB, Katz MJ, Davies P, Buschke H, Kuslansky G, Verghese J, Younkin SG, Eckman C, Dickson DW.

J Neuropathol Exp Neurol. 2005 May;64(5):378-85.

PMID:
15892294
16.

Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia.

Kotzbauer PT, Cairns NJ, Campbell MC, Willis AW, Racette BA, Tabbal SD, Perlmutter JS.

Arch Neurol. 2012 Oct;69(10):1326-31.

17.

Biochemical characterization of Abeta and tau pathologies in mild cognitive impairment and Alzheimer's disease.

Tremblay C, Pilote M, Phivilay A, Emond V, Bennett DA, Calon F.

J Alzheimers Dis. 2007 Dec;12(4):377-90.

PMID:
18198424
18.

Cortical alpha7 nicotinic acetylcholine receptor and beta-amyloid levels in early Alzheimer disease.

Ikonomovic MD, Wecker L, Abrahamson EE, Wuu J, Counts SE, Ginsberg SD, Mufson EJ, Dekosky ST.

Arch Neurol. 2009 May;66(5):646-51. doi: 10.1001/archneurol.2009.46.

19.

Disentangling the effects of age and APOE on neuropathology and late life cognitive decline.

Yu L, Boyle PA, Leurgans S, Schneider JA, Bennett DA.

Neurobiol Aging. 2014 Apr;35(4):819-26. doi: 10.1016/j.neurobiolaging.2013.10.074. Epub 2013 Oct 9.

20.

Cortical biochemistry in MCI and Alzheimer disease: lack of correlation with clinical diagnosis.

Forman MS, Mufson EJ, Leurgans S, Pratico D, Joyce S, Leight S, Lee VM, Trojanowski JQ.

Neurology. 2007 Mar 6;68(10):757-63.

PMID:
17339583

Supplemental Content

Support Center